Position in NUVL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$847,773
+$93,348 QoQ
Shares Held
8,275
+10.3% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NUVL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Shay Capital LLC holds $19,019,662 across 39 Biotechnology names. NUVL ranks #8 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
16,500 | $1,388,805 | |
| 2 | SRRK |
Scholar Rock Holding Corp
|
28,000 | $1,376,480 | |
| 3 | BCAX |
Bicara Therapeutics Inc.
|
63,500 | $1,263,015 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
12,000 | $1,167,000 | |
| 5 | MANE |
Veradermics, Inc
|
18,000 | $1,136,700 | |
| 6 | QURE |
uniQure N.V.
|
67,527 | $1,104,066 | |
| 7 | VYNE |
VYNE Therapeutics Inc.
|
1,610,242 | $962,924 | |
| 8 | NUVL |
Nuvalent, Inc.
This page
|
8,275 | $847,773 |
All Filings in NUVL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $847,773 | 8,275 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $754,425 | 7,500 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||